Witnessing the stock’s movement on the chart, on Thursday, Trevi Therapeutics Inc (NASDAQ: TRVI) set off with pace as it heaved 1.94% to $6.84, before settling in for the price of $6.71 at the close. Taking a more long-term approach, TRVI posted a 52-week range of $2.36-$7.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 27.09%. Meanwhile, its Annual Earning per share during the time was 27.09%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 8.52%. This publicly-traded company’s shares outstanding now amounts to $99.89 million, simultaneously with a float of $69.87 million. The organization now has a market capitalization sitting at $814.95 million. At the time of writing, stock’s 50-day Moving Average stood at $6.27, while the 200-day Moving Average is $4.80.
Trevi Therapeutics Inc (TRVI) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Trevi Therapeutics Inc’s current insider ownership accounts for 41.36%, in contrast to 47.38% institutional ownership. According to the most recent insider trade that took place on Mar 25 ’25, this organization’s Chief Scientific Officer sold 2,631 shares at the rate of 6.60, making the entire transaction reach 17,365 in total value, affecting insider ownership by 221,373. Preceding that transaction, on Mar 21 ’25, Company’s President & CEO sold 5,263 for 6.58, making the whole transaction’s value amount to 34,625. This particular insider is now the holder of 213,313 in total.
Trevi Therapeutics Inc (TRVI) Earnings and Revenue Records
Trevi Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 8.52% and is forecasted to reach -0.54 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -12.29% through the next 5 years, which can be compared against the 27.09% growth it accomplished over the previous five years trading on the market.
Trevi Therapeutics Inc (NASDAQ: TRVI) Trading Performance Indicators
Let’s observe the current performance indicators for Trevi Therapeutics Inc (TRVI). It’s Quick Ratio in the last reported quarter now stands at 15.38.
In the same vein, TRVI’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.45, a figure that is expected to reach -0.10 in the next quarter, and analysts are predicting that it will be -0.54 at the market close of one year from today.
Technical Analysis of Trevi Therapeutics Inc (TRVI)
Going through the that latest performance of [Trevi Therapeutics Inc, TRVI]. Its last 5-days volume of 1.77 million was inferior to the volume of 1.85 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 81.86% While, its Average True Range was 67.09%.
Raw Stochastic average of Trevi Therapeutics Inc (TRVI) in the period of the previous 100 days is set at 81.12%, which indicates a major fall in contrast to 87.20% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.34 that was lower than 0.42 volatility it exhibited in the past 100-days period.
